JP2007536920A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536920A5
JP2007536920A5 JP2007512116A JP2007512116A JP2007536920A5 JP 2007536920 A5 JP2007536920 A5 JP 2007536920A5 JP 2007512116 A JP2007512116 A JP 2007512116A JP 2007512116 A JP2007512116 A JP 2007512116A JP 2007536920 A5 JP2007536920 A5 JP 2007536920A5
Authority
JP
Japan
Prior art keywords
mammal
expression
responsive
cell proliferative
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007512116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536920A (ja
Filing date
Publication date
Priority claimed from GB0410883A external-priority patent/GB0410883D0/en
Priority claimed from GB0425257A external-priority patent/GB0425257D0/en
Application filed filed Critical
Priority claimed from PCT/EP2005/005269 external-priority patent/WO2005113801A2/en
Publication of JP2007536920A publication Critical patent/JP2007536920A/ja
Publication of JP2007536920A5 publication Critical patent/JP2007536920A5/ja
Pending legal-status Critical Current

Links

JP2007512116A 2004-05-14 2005-05-13 イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化 Pending JP2007536920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0410883A GB0410883D0 (en) 2004-05-14 2004-05-14 Organic compounds
GB0425257A GB0425257D0 (en) 2004-11-16 2004-11-16 Organic compounds
PCT/EP2005/005269 WO2005113801A2 (en) 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib

Publications (2)

Publication Number Publication Date
JP2007536920A JP2007536920A (ja) 2007-12-20
JP2007536920A5 true JP2007536920A5 (enExample) 2008-07-03

Family

ID=35295424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007512116A Pending JP2007536920A (ja) 2004-05-14 2005-05-13 イマチニブを用いる処置に感受性のある膠芽腫の小集団の同定および特性化

Country Status (9)

Country Link
US (1) US20080199855A1 (enExample)
EP (1) EP1756306A2 (enExample)
JP (1) JP2007536920A (enExample)
AU (1) AU2005245572B9 (enExample)
BR (1) BRPI0511088A (enExample)
CA (1) CA2564654A1 (enExample)
MX (1) MXPA06013079A (enExample)
RU (1) RU2006144122A (enExample)
WO (1) WO2005113801A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132336A1 (en) * 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
BR112012004237A8 (pt) * 2009-08-25 2016-10-04 Berg Pharma Llc métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)
EA201691257A1 (ru) * 2011-06-02 2017-02-28 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест на рак
HK1214633A1 (zh) 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829154B1 (fr) * 2001-09-05 2003-10-17 Assist Publ Hopitaux De Paris Nouveau procede de detection d'une mutation en phase de lecture dans une sequence codante et appareil pour sa mise en oeuvre
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP4035600B2 (ja) * 2002-05-22 2008-01-23 国立大学法人 東京大学 イマチニブに対する感受性の判定方法

Similar Documents

Publication Publication Date Title
JP6364488B2 (ja) 認知欠損を治療するための個別化医療的手法
Chang et al. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model
Choy et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways
Pertl et al. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy
Chahine et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations
Hu et al. Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment
Keizman et al. Low‐grade systemic inflammation in patients with amyotrophic lateral sclerosis
Limdi et al. Influence of kidney function on risk of supratherapeutic international normalized ratio–related hemorrhage in warfarin users: a prospective cohort study
Posadas-Sánchez et al. Interleukin 35 polymorphisms are associated with decreased risk of premature coronary artery disease, metabolic parameters, and IL‐35 levels: The genetics of atherosclerotic disease (GEA) study
JP6228302B2 (ja) プライマリーケアセッティングにおいて神経学的疾患を検出するための血液に基づくスクリーニング
US8158374B1 (en) Quantitative diagnostic methods using multiple parameters
US20110213219A1 (en) Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression
Patel et al. Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning
JP2008537474A5 (enExample)
O'Bryant et al. Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
Assis et al. A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients
Zhu et al. Genome-wide detection of m6A-associated genetic polymorphisms associated with ischemic stroke
CN116206776A (zh) 一种多基因snp位点介导的抗精神病药物血药浓度的预测模型及其构建方法和应用
Baos et al. Biomarkers associated with disease severity in allergic and nonallergic asthma
Kavalar et al. Association of ORMDL3, STAT6 and TBXA2R gene polymorphisms with asthma
Neubauer et al. Diagnostic Potential of Systemic Eosinophil‐Associated Cytokines and Growth Factors in IBD
Zhang et al. Serum cytokine profiles in patients with chronic obstructive pulmonary disease associated pulmonary hypertension identified using protein array
Tabouret et al. Predictive biomarkers investigated in glioblastoma
JP2007536920A5 (enExample)
Kuhlmann et al. The applications of biomarkers in early clinical drug development to improve decision-making processes